EDGAR Filing Documents for 0001725160-23-000119

Form 8-K - Current report:

SEC Accession No. 0001725160-23-000119

Filing Date

2023-05-26

Accepted

2023-05-26 12:38:56

Documents

Period of Report

2023-05-25

Items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	zntl-20230525.htm iXBRL	8-K	50373
2	EX-99.1	d2azenochemocomboasco05252.htm	EX-99.1	27786
6		image_0.jpg	GRAPHIC	24189
	Complete submission text file	0001725160-23-000119.txt		263405

Data Files

Seq	Description	Document	Type	Size
3	XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT	zntl-20230525.xsd	EX-101.SCH	1902
4	XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT	zntl-20230525_lab.xml	EX-101.LAB	24849
5	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT	zntl-20230525_pre.xml	EX-101.PRE	13046
8	EXTRACTED XBRL INSTANCE DOCUMENT	zntl-20230525_htm.xml	XML	11258

Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018

Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791

Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 23966142
SIC: 2834 Pharmaceutical Preparations